tetrachlorophenol: RN given refers to cpd with unspecified isomeric designation; see also record for 2,3,4,6-tetrachlorophenol
tetrachlorophenol : A chlorophenol that is phenol in which four of the hydrogens attached to the benzene ring are replaced by chlorines.
2,3,4,5-tetrachlorophenol : A tetrachlorophenol in which the chlorines are located at positions 2, 3, 4, and 5.
ID Source | ID |
---|---|
PubMed CID | 21013 |
CHEMBL ID | 1528479 |
CHEBI ID | 132357 |
SCHEMBL ID | 202648 |
MeSH ID | M0118633 |
Synonym |
---|
phenol, 2,3,4,5-tetrachloro- |
2,3,4,5-tetrachlorophenol |
25167-83-3 |
tetrachlorophenol |
4901-51-3 |
NCGC00091833-01 |
hsdb 6765 |
einecs 225-531-7 |
2,3,4,5-tetrachlorophenate |
brn 2049590 |
ccris 4722 |
CHEBI:132357 |
2,3,4,5-tecp |
1-hydroxy-2,3,4,5-tetrachlorobenzene |
MLS002415677 , |
smr000312345 |
inchi=1/c6h2cl4o/c7-2-1-3(11)5(9)6(10)4(2)8/h1,11h |
rulkyxxcczzkdz-uhfffaoysa- |
NCGC00091833-03 |
NCGC00091833-02 |
dtxsid0022220 , |
tox21_200105 |
cas-4901-51-3 |
NCGC00257659-01 |
dtxcid202220 |
unii-d2uw5nhw9j |
4-06-00-01020 (beilstein handbook reference) |
d2uw5nhw9j , |
cid_21013 |
bdbm96279 |
2,3,4,5-tetrakis(chloranyl)phenol |
AKOS015888369 |
SCHEMBL202648 |
tetrachlorophenol, 2,3,4,5- |
2,3,4,5-tetrachlorophenol [hsdb] |
RULKYXXCCZZKDZ-UHFFFAOYSA-N |
CHEMBL1528479 |
2,?3,?4,?5-?tetrachlorophenol |
2,3,4,5-tetrachlorophenol, analytical standard |
2,3,4,5-tetrachlorophenol 100 microg/ml in methanol |
phenol, 2,3,4,5-tetrachloro-; 2,3,4,5-tetrachlorophenol |
2,3,4,5-tetrachlorophenol 10 microg/ml in cyclohexane |
mfcd00053449 |
Q26840906 |
1,3-piperidinedicarboxylicacid, 1-(phenylmethyl) ester |
PD131514 |
Excerpt | Relevance | Reference |
---|---|---|
" Comparisons were made with the general BC population and dose-response relationships were assessed using Poisson regression." | ( Cancer and occupational exposure to pentachlorophenol and tetrachlorophenol (Canada). Davies, HW; Demers, PA; Friesen, MC; Hershler, R; Hertzman, C; Ostry, A; Teschke, K, 2006) | 0.33 |
" Internal analyses showed strong dose-response relationships for non-Hodgkin's lymphoma, multiple myeloma, and kidney cancer." | ( Cancer and occupational exposure to pentachlorophenol and tetrachlorophenol (Canada). Davies, HW; Demers, PA; Friesen, MC; Hershler, R; Hertzman, C; Ostry, A; Teschke, K, 2006) | 0.33 |
Role | Description |
---|---|
xenobiotic metabolite | Any metabolite produced by metabolism of a xenobiotic compound. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
tetrachlorophenol | A chlorophenol that is phenol in which four of the hydrogens attached to the benzene ring are replaced by chlorines. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 87.3212 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 7.9433 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 26.9002 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 24.2333 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 38.5975 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 38.5975 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 30.0550 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 34.8119 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063 |
Smad3 | Homo sapiens (human) | Potency | 7.0795 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
PINK1 | Homo sapiens (human) | Potency | 14.1254 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 39.8107 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 13.3660 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 49.4654 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839 |
progesterone receptor | Homo sapiens (human) | Potency | 21.1836 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 19.3981 | 0.0002 | 14.3764 | 60.0339 | AID588533; AID720692; AID720719 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 50.3175 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 15.9395 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 25.8297 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 53.6730 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 33.5738 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 39.1229 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID588513; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
Parkin | Homo sapiens (human) | Potency | 14.1254 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 50.0164 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID743212 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 21.6118 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743094; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 25.1189 | 0.0237 | 23.2282 | 63.5986 | AID588543 |
IDH1 | Homo sapiens (human) | Potency | 25.9290 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 11.6881 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 66.9885 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 55.4464 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 37.9976 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
tumor necrosis factor | Homo sapiens (human) | Potency | 74.9780 | 0.3758 | 23.4928 | 42.1632 | AID651757 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 11.2202 | 0.0018 | 15.6638 | 39.8107 | AID894 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 44.6684 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 79.4328 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 13.4546 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 34.3757 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 13.0715 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 50.1187 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 14.5810 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 7.9433 | 0.0200 | 10.7869 | 31.6228 | AID912 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 29.9226 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 22.5659 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 29.9226 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Alpha-synuclein | Homo sapiens (human) | Potency | 7.0795 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 23.7101 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
exodeoxyribonuclease V subunit RecB | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 63.5370 | 0.1000 | 0.1000 | 0.1000 | AID652151 |
exodeoxyribonuclease V subunit RecC | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 63.5370 | 0.1000 | 0.1000 | 0.1000 | AID652151 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | AC50 | 2.0600 | 0.1950 | 3.6679 | 18.6960 | AID540270 |
heat shock protein 90, putative | Plasmodium falciparum 3D7 | AC50 | 1.7030 | 0.1950 | 4.9920 | 98.5000 | AID540268 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 9 (31.03) | 18.7374 |
1990's | 2 (6.90) | 18.2507 |
2000's | 12 (41.38) | 29.6817 |
2010's | 5 (17.24) | 24.3611 |
2020's | 1 (3.45) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.63) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 29 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |